PMID- 37996207
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20231211
IS  - 1557-8445 (Electronic)
IS  - 0065-2776 (Linking)
VI  - 159
DP  - 2023
TI  - The show and tell of cross-presentation.
PG  - 33-114
LID - S0065-2776(23)00028-7 [pii]
LID - 10.1016/bs.ai.2023.08.002 [doi]
AB  - Cross-presentation is the culmination of complex subcellular processes that allow 
      the processing of exogenous proteins and the presentation of resultant peptides 
      on major histocompatibility class I (MHC-I) molecules to CD8 T cells. Dendritic 
      cells (DCs) are a cell type that uniquely specializes in cross-presentation, 
      mainly in the context of viral or non-viral infection and cancer. DCs have an 
      extensive network of endovesicular pathways that orchestrate the biogenesis of an 
      ideal cross-presentation compartment where processed antigen, MHC-I molecules, 
      and the MHC-I peptide loading machinery all meet. As a central conveyor of 
      information to CD8 T cells, cross-presentation allows cross-priming of T cells 
      which carry out robust adaptive immune responses for tumor and viral clearance. 
      Cross-presentation can be canonical or noncanonical depending on the functional 
      status of the transporter associated with antigen processing (TAP), which in turn 
      influences the vesicular route of MHC-I delivery to internalized antigen and the 
      cross-presented repertoire of peptides. Because TAP is a central node in MHC-I 
      presentation, it is targeted by immune evasive viruses and cancers. Thus, 
      understanding the differences between canonical and noncanonical 
      cross-presentation may inform new therapeutic avenues against cancer and 
      infectious disease. Defects in cross-presentation on a cellular and genetic level 
      lead to immune-related disease progression, recurrent infection, and cancer 
      progression. In this chapter, we review the process of cross-presentation 
      beginning with the DC subsets that conduct cross-presentation, the signals that 
      regulate cross-presentation, the vesicular trafficking pathways that orchestrate 
      cross-presentation, the modes of cross-presentation, and ending with disease 
      contexts where cross-presentation plays a role.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Blander, J Magarian
AU  - Blander JM
AD  - Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell 
      Medicine, Cornell University, New York, NY, United States; Joan and Sanford I. 
      Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New 
      York, NY, United States; Department of Microbiology and Immunology, Weill Cornell 
      Medicine, Cornell University, New York, NY, United States; Sandra and Edward 
      Meyer Cancer Center, Weill Cornell Medicine, Cornell University, New York, NY, 
      United States; Immunology and Microbial Pathogenesis Programs, Weill Cornell 
      Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, 
      New York, NY, United States. Electronic address: jmblander@med.cornell.edu.
FAU - Yee Mon, Kristel Joy
AU  - Yee Mon KJ
AD  - Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell 
      Medicine, Cornell University, New York, NY, United States; Joan and Sanford I. 
      Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New 
      York, NY, United States.
FAU - Jha, Atimukta
AU  - Jha A
AD  - Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell 
      Medicine, Cornell University, New York, NY, United States; Joan and Sanford I. 
      Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New 
      York, NY, United States.
FAU - Roycroft, Dylan
AU  - Roycroft D
AD  - Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell 
      Medicine, Cornell University, New York, NY, United States; Joan and Sanford I. 
      Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New 
      York, NY, United States.
LA  - eng
GR  - R01 AI170832/AI/NIAID NIH HHS/United States
GR  - R01 AI170897/AI/NIAID NIH HHS/United States
GR  - R21 AI159772/AI/NIAID NIH HHS/United States
GR  - T32 DK116970/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231012
PL  - United States
TA  - Adv Immunol
JT  - Advances in immunology
JID - 0370425
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Antigens)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Peptides)
SB  - IM
MH  - Humans
MH  - *Cross-Priming
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Dendritic Cells
MH  - Antigen Presentation
MH  - CD8-Positive T-Lymphocytes
MH  - Antigens/metabolism
MH  - Membrane Transport Proteins/metabolism
MH  - Peptides/metabolism
MH  - *Neoplasms/metabolism
OTO - NOTNLM
OT  - Bacteria
OT  - CDC1
OT  - CDC2
OT  - Cancer
OT  - Chlamydia
OT  - Cross-presentation
OT  - Dendritic cells
OT  - Endosomal recycling compartment
OT  - Immune evasion
OT  - MHC-I
OT  - Mycobacteria
OT  - SNARE
OT  - Toll-like receptor
OT  - Transporter associated with antigen processing
OT  - Vesicular traffic
OT  - Virus
EDAT- 2023/11/24 00:42
MHDA- 2023/11/27 12:44
CRDT- 2023/11/23 20:59
PHST- 2023/11/27 12:44 [medline]
PHST- 2023/11/24 00:42 [pubmed]
PHST- 2023/11/23 20:59 [entrez]
AID - S0065-2776(23)00028-7 [pii]
AID - 10.1016/bs.ai.2023.08.002 [doi]
PST - ppublish
SO  - Adv Immunol. 2023;159:33-114. doi: 10.1016/bs.ai.2023.08.002. Epub 2023 Oct 12.